Non-small cell lung cancer (NSCLC) is the most common form, accounting for approximately 85% of all lung cancers.2 Many people diagnosed with early-stage NSCLC have surgery to remove the cancer; however, for approximately half of these patients, the cancer unfortunately returns.3 Experts agree there is an urgent need for enhanced screening uptake — which has hovered around five percent in recent years amongst those eligible to receive it4 — as well as improved treatment options in early-stage NSCLC to help prevent devastating cancer recurrences.

Studies have shown that treatments beyond chemotherapy, including targeted therapy and now immunotherapy – a type of personalized cancer treatment that activates the immune system to fight cancer – may help improve outcomes for certain patients with early-stage NSCLC after surgery.5 What’s promising is that these studies have now led to U.S. Food and Drug Administration approvals in the post-surgery setting to help reduce the risk of recurrence for patients with specific types of early-stage NSCLC, introducing a new era for these lung cancer patients.

Dr. David Carbone, Professor of Internal Medicine and Director of the James Thoracic Oncology Center at Ohio State University Medical Center will discuss the latest progress, including one of the most recent developments in early-stage lung cancer for patients.

Interview courtesy: Genentech

1 ACS. Key Statistics for Lung Cancer. 2022. Accessed from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
2 Molina et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008 May; 83(5): 584–594. Accessed September 27, 2021.
3 Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin
Oncol. 2014;5(5):1048-1054. doi:10.5306/wjco.v5.i5.1048
4 Fedewa SA, Kazerooni EA, Studts JL, et al. State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States. JNCI: The Journal of the National Cancer Institute. doi: 10.1093/jnci/djaa170
5 Zappa et al. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300. doi:
10.21037/tlcr.2016.06.07.

#davidcarbone #lungcancer #genentech #americancancersociety #factsfigures #disease #aminotherapy #etizolam #go2foundation #nsclc #surgery #chemotherapy #medicine #treatments #patients

The post EXCITING PROGRESS IN DIAGNOSING AND TREATING EARLY-STAGE LUNG CANCER appeared first on Good News!.

Find Out More About this Condition. Capsian Patch, … can be considered. a specific approved product is Qutinza
More than 34 million Americans – just over 1 in 10 – have diabetes1, and neuropathic pain associated with diabetic peripheral neuropathy of the feet, or more commonly referred to as diabetic nerve pain, is one of its most common complications.2
The painful symptoms associated with this nerve damage include numbness, tingling, as well as shooting or stabbing sensations that most often affect the lower extremities.3
Itis a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20204 and is expected to double by 2030.5
Joining us now to discuss neuropathic pain associated with diabetic peripheral neuropathy – or diabetic nerve pain – and this newly approved treatment option is Dr. David Simpson, Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York City.
Key Facts and Figures:
• The lack of effective, innovative treatment options has left many patients with a significant unmet medical need.
• The condition is more common in patients with type 2 diabetes and increases with age and duration of disease.
When you book a window, we’ll provide you with guest bio & suggested questions. The interview is courtesy of Averitas Pharma, Inc.
References:
1. CDC Division of Diabetes Translation, National Diabetes Statistics Report, 2020. https://www.cdc.gov/diabetes/library/features/diabetes-stat-report.html#:~:text=New%20in%202020%2C%20the%20report,1%20in%203%E2%80%94have%20prediabetes. Accessed July 6, 2020
2. University of Chicago Center for Peripheral Neuropathy. Types of peripheral Neuropathy. http://peripheralneuropathycenter.uchicago.edu/learnaboutpn/typesofpn/diabetes/diabetes.shtml. Accessed July 6,2020
3. American Diabetes Association. Peripheral NeuorapthyOverview. https://www.diabetes.org/diabetes/complications/neuropathy/peripheral-neuropathy.Accessed July 17, 2020
4. LTP2020-2030: ADDRESSABLE POPULATIONS BY CONDITION (PDPN, PSNP, PHN, CINP).Company data on file. April 30, 2020.
5. Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L.,Tai, K.-S., & Stacey, B. (2005). Pain Severity in Diabetic Peripheral Neuropathy is Associated with patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management, 30(4),374-385. doi:10.1016/j.jpainsymman.2005.04.009.
https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html
6. CDC,Behavioral Risk Factor Surveillance System, 2018
7. America’sHealth Rankings. United Health Foundation.https://www.americashealthrankings.org/explore/annual/measure/Diabetes. Accessed July 13, 2020

The post DIABETIC NERVE PAIN WILL AFFECT APPROXIMATELY 5 MILLION AMERICANS IN 2020 appeared first on Good News!.